Reviewer's report

Title: Stereotactic Body Radiotherapy for Organ-Confined Prostate Cancer

Version: 2 Date: 12 November 2009

Reviewer: Satoshi Anai

Reviewer's report:

Authors described here that the Stereotactic Body Radiotherapy (SBRT) for Organ-Confined Prostate Cancer would be feasible and less toxic compared with the conventional radiotherapy. Hopefully this novel radiotherapy will be the new generation for localized prostate cancer treatment. The treatment period of SBRT is for just 5 days. This would provide patients with the benefits of time and cost issue. However this study has the two limitations. One is the short follow-up period for the biochemical failure and the QOL. The other is that it is too difficult to identify if the lower rectal toxicities owe to the SBRT or the rectal administration of amifostine. Referring to the QOL, authors mentioned that this study’s follow up period was similar to the Sanda et al. study. But the ultimate aim of the treatment for the prostate cancer is to eliminate the cancer completely. So the further follow up for both QOL and the biochemical recurrence must be mandatory for this study. I wish authors would report the longer outcome of this treatment.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.